In recent trading session, Repare Therapeutics Inc (NASDAQ:RPTX) saw 0.44 million shares changing hands at last check today with its beta currently measuring 0.88. Company’s recent per share price level of $1.26 trading at -$0.02 or -1.56% at last check today assigns it a market valuation of $53.56M. That most recent trading price of RPTX’s stock is at a discount of -573.81% from its 52-week high price of $8.49 and is indicating a premium of 4.76% from its 52-week low price of $1.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.54 million shares which gives us an average trading volume of 370.39K if we extend that period to 3-months.
For Repare Therapeutics Inc (RPTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.57. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.79 in the current quarter.
Repare Therapeutics Inc (NASDAQ:RPTX) trade information
Upright in the red during last session for losing -1.56%, in the last five days RPTX remained trading in the red while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $1.26 price level, adding 14.86% to its value on the day. Repare Therapeutics Inc’s shares saw a change of -3.82% in year-to-date performance and have moved -4.55% in past 5-day. Repare Therapeutics Inc (NASDAQ:RPTX) showed a performance of -59.09% in past 30-days. Number of shares sold short was 0.85 million shares which calculate 1.72 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 87.4% to its recent value today. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -693.65% in reaching the projected high whereas dropping to the targeted low would mean a loss of -693.65% for stock’s current value.
Repare Therapeutics Inc (RPTX) estimates and forecasts
Statistics highlight that Repare Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -64.51% of value to its shares in past 6 months, showing an annual growth rate of 5.83% while that of industry is 16.50. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 8.98% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.73M for the same. And 5 analysts are in estimates of company making revenue of 2.34M in the next quarter. Company posted 13.05M and 52.4M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -41.74% during past 5 years.
Repare Therapeutics Inc (NASDAQ:RPTX)’s Major holders
Insiders are in possession of 0.95% of company’s total shares while institution are holding 84.60 percent of that, with stock having share float percentage of 85.41%. Investors also watch the number of corporate investors in a company very closely, which is 84.60% institutions for Repare Therapeutics Inc that are currently holding shares of the company. BVF INC/IL is the top institutional holder at RPTX for having 10.33 million shares of worth $34.1 million. And as of 2024-06-30, it was holding 24.4675 of the company’s outstanding shares.
The second largest institutional holder is BLUE OWL CAPITAL HOLDINGS LP, which was holding about 3.37 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.9853 of outstanding shares, having a total worth of $11.13 million.
On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Health Care Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024, the former fund manager was holding 2.17 shares of worth $2.72 million or 5.10% of the total outstanding shares. The later fund manager was in possession of 55.24 shares on Aug 31, 2024, making its stake of worth around $69327.0 in the company or a holder of 0.13% of company’s stock.
